Neurocrine Biosciences to Participate at Investor Conferences in September
Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this September. The company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024, at 3:20 p.m. ET, and the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, at 8:45 a.m. ET.
Key executives, including CEO Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and CFO Matt Abernethy, will represent the company. Both presentations will be webcast live and accessible on Neurocrine's website, with replays available for approximately one month.
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments and a robust pipeline of compounds in clinical development.
Neurocrine Biosciences (NBIX) ha annunciato la sua partecipazione a due importanti conferenze per investitori questo settembre. L'azienda presenterà alla 22ª Conferenza Annuale sulla Salute Globale di Morgan Stanley a New York il 4 settembre 2024, alle 15:20 ET, e alla Conferenza sulla Salute di Wells Fargo 2024 a Boston il 5 settembre 2024, alle 8:45 ET.
I principali dirigenti, tra cui il CEO Kevin Gorman, il Chief Business Development and Strategy Officer Kyle Gano e il CFO Matt Abernethy, rappresenteranno l'azienda. Entrambe le presentazioni saranno trasmesse in diretta e accessibili sul sito di Neurocrine, con riproduzioni disponibili per circa un mese.
Neurocrine Biosciences è una delle principali aziende biofarmaceutiche focalizzate sulla neuroscienza, dedicata allo sviluppo di trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici. Il loro portafoglio include trattamenti approvati dalla FDA e un ampio pipeline di composti in sviluppo clinico.
Neurocrine Biosciences (NBIX) ha anunciado su participación en dos importantes conferencias para inversores este septiembre. La compañía presentará en la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York el 4 de septiembre de 2024, a las 3:20 p.m. ET, y en la Conferencia de Salud 2024 de Wells Fargo en Boston el 5 de septiembre de 2024, a las 8:45 a.m. ET.
Ejecutivos clave, incluido el CEO Kevin Gorman, el Director de Desarrollo de Negocios y Estrategia Kyle Gano, y el CFO Matt Abernethy, representarán a la compañía. Ambas presentaciones se transmitirán en vivo y estarán disponibles en el sitio web de Neurocrine, con repeticiones accesibles por aproximadamente un mes.
Neurocrine Biosciences es una de las principales empresas biofarmacéuticas centradas en la neurociencia, dedicada al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. Su portafolio incluye tratamientos aprobados por la FDA y un sólido pipeline de compuestos en desarrollo clínico.
뉴로크라인 바이오사이언스(NBIX)는 이번 9월 두 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 2024년 9월 4일 오후 3시 20분 ET에 뉴욕에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스와 2024년 9월 5일 오전 8시 45분 ET에 보스턴에서 열리는 웰스파고 헬스케어 컨퍼런스 2024에서 발표할 예정입니다.
CEO 케빈 고먼, 사업 개발 및 전략 책임자 카일 가노, CFO 맷 에버네시와 같은 주요 경영진이 회사를 대표합니다. 두 발표 모두 실시간 웹캐스트로 제공되며, 뉴로크라인 웹사이트에서 접근할 수 있고, 약 한 달 동안 다시 볼 수 있습니다.
뉴로크라인 바이오사이언스는 신경과학에 중점을 둔 선도적인 생물 제약 회사로, 신경학적, 신경내분비 및 신경정신 장애 치료제를 개발하는 데 전념하고 있습니다. 이들의 포트폴리오에는 FDA 승인을 받은 치료제와 임상 개발 중인 강력한 파이프라인이 포함되어 있습니다.
Neurocrine Biosciences (NBIX) a annoncé sa participation à deux grandes conférences pour investisseurs ce mois de septembre. L'entreprise présentera à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York le 4 septembre 2024, à 15h20 ET, et à la Conférence Santé 2024 de Wells Fargo à Boston le 5 septembre 2024, à 8h45 ET.
Des cadres clés, y compris le PDG Kevin Gorman, le Responsable du Développement et de la Stratégie des Affaires Kyle Gano, et le CFO Matt Abernethy, représenteront l'entreprise. Les deux présentations seront diffusées en direct et accessibles sur le site web de Neurocrine, avec des rediffusions disponibles pendant environ un mois.
Neurocrine Biosciences est une entreprise biopharmaceutique de premier plan axée sur les neurosciences, dédiée à développer des traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques. Leur portefeuille comprend des traitements approuvés par la FDA et un solide pipeline de composés en développement clinique.
Neurocrine Biosciences (NBIX) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September bekannt gegeben. Das Unternehmen wird am 4. September 2024 um 15:20 Uhr ET auf der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley in New York und am 5. September 2024 um 8:45 Uhr ET auf der Wells Fargo Healthcare Conference 2024 in Boston auftreten.
Wichtige Führungskräfte, darunter CEO Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano und CFO Matt Abernethy, werden das Unternehmen vertreten. Beide Präsentationen werden live übertragen und sind auf der Website von Neurocrine verfügbar, mit Wiederholungen, die etwa einen Monat lang zugänglich sind.
Neurocrine Biosciences ist ein führendes biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und sich der Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Störungen widmet. Ihr Portfolio umfasst von der FDA zugelassene Behandlungen und eine robuste Pipeline von Verbindungen in der klinischen Entwicklung.
- None.
- None.
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in
2024 Wells Fargo Healthcare Conference on September 5 in
- Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in
New York at 3:20 p.m. Eastern Time on Wednesday, September 4, 2024. - Kyle Gano and Matt Abernethy will present at the 2024 Wells Fargo Healthcare Conference in
Boston at 8:45 a.m. Eastern Time on Thursday, September 5, 2024.
The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-302233393.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When and where is Neurocrine Biosciences (NBIX) presenting at investor conferences in September 2024?
Who will be representing Neurocrine Biosciences (NBIX) at these investor conferences?
How can investors access Neurocrine Biosciences' (NBIX) presentations at the September 2024 conferences?
What are the main therapeutic areas Neurocrine Biosciences (NBIX) focuses on?
